Table 4.
Adenoviral vector‐based RSV vaccines in clinical trials
| Vaccine | Company/Sponsor | Vector | Replication | Route | Antigen/s | Target population | Phase | NCT |
|---|---|---|---|---|---|---|---|---|
| Ad26.RSV.PreF | Janssen | HAd26 | Defective | Intramuscular | Pre‐F | 12–24‐month‐old | II | NCT03606512 |
| Ad26.RSV.PreF | Janssen | HAd26 | Defective | Intramuscular | Pre‐F | 60 years and older | I | NCT03339713 |
| ChAd155.‐RSV | GSK | ChAd155 | Defective | Intramuscular | F, N, M2‐1 | 18–45‐year‐old | I | NCT02491463 |
| VXA.RSV.F | Vaxart | HAd5 | Defective | Oral | F | 18–49‐year‐old | I | NCT02830932 |
ChAd155, chimpanzee adenovirus type 155; F, fusion protein; HAd26, human adenovirus type 26; HAd5, human adenovirus type 5; M, matrix protein; N, nucleoprotein; NCT, national clinical trial; Pre‐F, pre‐fusion protein; RSV, respiratory syncytial virus.